Log in

NYSE:MDTMedtronic Stock Price, Forecast & News

$86.27
+0.12 (+0.14 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$84.78
Now: $86.27
$87.49
50-Day Range
$72.92
MA: $97.14
$117.33
52-Week Range
$72.13
Now: $86.27
$122.15
Volume5.62 million shs
Average Volume6.90 million shs
Market Capitalization$115.62 billion
P/E Ratio21.90
Dividend Yield2.51%
Beta0.7
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More
Medtronic logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.3Dividend Strength: 5.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

3.47 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP58505510
Phone353-1438-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.56 billion
Cash Flow$7.46 per share
Book Value$38.77 per share

Profitability

Net Income$4.63 billion

Miscellaneous

Employees90,000
Outstanding Shares1,340,166,000
Market Cap$115.62 billion
Next Earnings Date5/28/2020 (Estimated)
OptionableOptionable

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.


Medtronic (NYSE:MDT) Frequently Asked Questions

How has Medtronic's stock been impacted by COVID-19 (Coronavirus)?

Medtronic's stock was trading at $92.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDT stock has decreased by 6.7% and is now trading at $86.27. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Medtronic?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 1 sell rating, 3 hold ratings and 22 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Medtronic.

When is Medtronic's next earnings date?

Medtronic is scheduled to release its next quarterly earnings announcement on Thursday, May 28th 2020. View our earnings forecast for Medtronic.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) issued its quarterly earnings results on Tuesday, February, 18th. The medical technology company reported $1.44 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.38 by $0.06. The medical technology company earned $7.72 billion during the quarter, compared to analysts' expectations of $7.80 billion. Medtronic had a return on equity of 14.76% and a net margin of 17.11%. The company's revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.29 EPS. View Medtronic's earnings history.

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Tuesday, March 10th. Shareholders of record on Friday, March 27th will be given a dividend of $0.54 per share on Friday, April 17th. This represents a $2.16 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date of this dividend is Thursday, March 26th. View Medtronic's dividend history.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic updated its fourth quarter earnings guidance on Tuesday, February, 18th. The company provided earnings per share (EPS) guidance of $1.64 for the period, compared to the Thomson Reuters consensus estimate of $1.63.

What price target have analysts set for MDT?

26 Wall Street analysts have issued twelve-month price objectives for Medtronic's shares. Their forecasts range from $90.00 to $135.00. On average, they expect Medtronic's share price to reach $117.85 in the next twelve months. This suggests a possible upside of 36.6% from the stock's current price. View analysts' price targets for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:
  • 1. Northland Securities analysts commented, "We continue to wait for a definitive breakout in key categories in terms of growth. In fairness, Medtronic continues to improve operational efficiencies." (8/21/2019)
  • 2. Needham & Company LLC analysts commented, "Market open, Ellex announced preliminary FY19 revenue below our expectations and IFRS EBITDA slightly narrower than our expectations. iTrack, 2RT and Tango lasers delivered FY19 y/y revenue growth, but overall growth was below our estimates. Ellex announced the appointment of Maria Maieli, current CFO, as Interim CEO. Ellex expects to release final F2H19 results on August 29, 2019." (7/23/2019)
  • 3. According to Zacks Investment Research, "The declining CRHF segment raises concern for Medtronic. Escalating costs and expenses continue to weigh on Medtronic’s bottom line. On a positve note, in the past year, shares of Medtronic outperformed its industry. The company is successfully registering sustainable growth across major groups and regions, in addition to displaying successful achievement of synergy targets. The company is focusing on geographical diversification of its businesses. This apart, the company has been seeing certain favorable developments in its Diabetes business. The updated 2019 guidance with raised EPS view increases investors’ confidence on the stock. Meanwhile, we are optimistic about the recently-closed acquisition of Mazor Robotics which is expected to fortify Medtronic's position in spine surgery." (5/20/2019)

Has Medtronic been receiving favorable news coverage?

Media headlines about MDT stock have been trending very negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medtronic earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutMedtronic.

Are investors shorting Medtronic?

Medtronic saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 12,232,100 shares, an increase of 22.8% from the February 27th total of 9,960,000 shares. Based on an average trading volume of 4,960,000 shares, the days-to-cover ratio is currently 2.5 days. Currently, 0.9% of the shares of the stock are sold short. View Medtronic's Current Options Chain.

Who are some of Medtronic's key competitors?

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV), Cisco Systems (CSCO), Home Depot (HD), CVS Health (CVS), Intel (INTC) and Starbucks (SBUX).

Who are Medtronic's key executives?

Medtronic's management team includes the following people:
  • Mr. Omar S. Ishrak, Chairman & CEO (Age 63)
  • Ms. Karen L. Parkhill, Exec. VP, CFO & Principal Accounting Officer (Age 54)
  • Mr. Bradley E. Lerman, Sr. VP, Gen. Counsel & Company Sec. (Age 61)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 57)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 58)

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Who are Medtronic's major shareholders?

Medtronic's stock is owned by many different retail and institutional investors. Top institutional investors include Woodstock Corp (0.01%), Cullinan Associates Inc. (0.01%), Park National Corp OH (0.00%), Fulton Bank N.A. (0.00%), Deane Retirement Strategies Inc. (0.00%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Medtronic stock include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, Karen L Parkhill, Michael J Coyle, Omar Ishrak, Richard H Anderson, Richard Kuntz and Robert John White. View institutional ownership trends for Medtronic.

Which institutional investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A., Cullinan Associates Inc., Blackhawk Capital Partners LLC., Park National Corp OH, Woodstock Corp, Deane Retirement Strategies Inc., and Thomasville National Bank. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, Michael J Coyle, Richard Kuntz, and Robert John White. View insider buying and selling activity for Medtronic.

Which institutional investors are buying Medtronic stock?

MDT stock was purchased by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought Medtronic stock in the last two years include Karen L Parkhill, Omar Ishrak, and Richard H Anderson. View insider buying and selling activity for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $86.27.

How big of a company is Medtronic?

Medtronic has a market capitalization of $115.62 billion and generates $30.56 billion in revenue each year. The medical technology company earns $4.63 billion in net income (profit) each year or $5.22 on an earnings per share basis. Medtronic employs 90,000 workers across the globe. View additional information about Medtronic.

What is Medtronic's official website?

The official website for Medtronic is http://www.medtronic.com/.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: What is a resistance level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel